Expanded TIMI Risk Score Deemed Practical in DiabetesLast Updated: December 15, 2017. The TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Secondary Prevention is an accurate predictor of atherothrombotic disease among patients with type 2 diabetes, according to a study published online Dec. 1 in Diabetes Care.
FRIDAY, Dec. 15, 2017 (HealthDay News) -- The TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2°P) is an accurate predictor of atherothrombotic disease among patients with type 2 diabetes, according to a study published online Dec. 1 in Diabetes Care.
Brian A. Bergmark, M.D., from Brigham and Women's Hospital in Boston, and colleagues assessed the TRS 2°P in patients with type 2 diabetes by comparing baseline TRS 2°P in a cohort of 16,488 patients (participating in SAVOR-TIMI 53) with type 2 diabetes and high cardiovascular (CV) risk or established CV disease.
The researchers found that TRS 2°P resulted in a robust risk gradient for the composite outcome of CV death, myocardial infarction (MI), and ischemic stroke. Among the full cohort, two-year event rates were 0.9 percent in the lowest- and 19.8 percent in the highest-risk groups (Ptrend < 0.001). Within subgroups, including all coronary artery disease (CAD), CAD without prior MI, CAD with prior MI, peripheral artery disease, and prior stroke, a clear risk gradient was detected (Ptrend < 0.001 for each). Similar results were seen with the type 2 diabetes cohort from the REACH Registry (goodness-of-fit P = 0.78).
"The expanded TRS 2°P provides a practical and well-calibrated risk prediction tool for patients with type 2 diabetes," the authors write.
Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Bristol-Myers Squibb, which funded the study.
|Previous: Contrast-Enhanced Ultrasound No Aid for Metastasis Detection||Next: Multiple Myeloma Survival Down With High ADAR1 RNA Expression|
Reader comments on this article are listed below. Review our comments policy.